Talking Treatment Strategies for Breast Cancer in Pittsburgh
January 10th 2019We traveled to Pittsburgh, Pennsylvania for a State of the Science Summit on Breast Cancer, which focused on novel approaches in metastatic triple-negative breast cancer and treatment strategies for patients with brain metastases.
Read More
John Mendelsohn, MD Anderson President Emeritus, Passes Away
January 8th 2019John Mendelsohn, MD, president emeritus of The University of Texas MD Anderson Cancer Center and an internationally acclaimed leader in the field of medicine and scientist whose research helped pioneer a new type of cancer therapy, died January 7, 2019 at his home in Houston, Texas.
Read More
Snapshot of the 2018 ASH Annual Meeting in San Diego
January 4th 2019We traveled to San Diego, California, for the 2018 ASH Annual Meeting, where we spoke with several experts across hematologic malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma.
Read More
MD Anderson Notes Passing of Waun Ki Hong: Innovator, Mentor, Colleague
January 4th 2019Waun Ki Hong, MD, a trail-blazing physician-scientist, mentor, and 2018 Giant of Cancer Care® in Head and Neck Cancers, whose clinical research innovations led to successful organ-sparing cancer treatment, advanced the field of targeted therapy and launched chemoprevention, died Wednesday at his home in California.
Read More
Buzzing With News From the San Antonio Breast Cancer Symposium
December 26th 2018We headed to San Antonio, Texas, for the San Antonio Breast Cancer Symposium, where we spoke to several principal investigators who detailed new applications of novel therapies, surgical intervention strategies, and lifestyle modifications.
Read More
ECHELON-1 Analysis Shows Brentuximab Vedotin Activity in Nonpediatric AYA Hodgkin Lymphoma
December 13th 2018Nonpediatric young adults with stage III/IV Hodgkin lymphoma had significantly better progression-free survival when treated with brentuximab vedotin and conventional chemotherapy compared with standard therapy.
Read More
Acalabrutinib Achieves High Response Rates in CLL
December 11th 2018Patients with newly diagnosed or relapsed/refractory chronic lymphocytic leukemia achieved objective response rates as high as 100% with either of 2 doses of the BTK inhibitor acalabrutinib, results of an open-label phase II trial showed.
Read More
ACCC Welcomes Leigh M. Boehmer, PharmD, BCOP, as Medical Director of Education
December 11th 2018The Association of Community Cancer Centers is pleased to announce the hiring of Leigh M. Boehmer, PharmD, BCOP, as Medical Director, Education, for the association’s expanding education initiatives.
Read More
TAILORx Analysis Underscores Racial Disparity in Breast Cancer Outcomes
December 11th 2018African-American patients with early breast cancer had worse outcomes than Caucasian patients following adjuvant therapy, despite having a similar risk of recurrence and receiving similar types of therapy, according to subgroup analysis of the phase III TAILORx trial.
Read More
ACCC and Pfizer Award $1.8 Million in Funding for Improvement in Breast Cancer Genetic Testing
December 6th 2018The Association of Community Cancer Centers announced today that it has partnered with Pfizer Global Medical Grants to award more than $1.8 million in funding to 15 projects that are aimed at improving the quality of breast cancer patient care.
Read More
Venetoclax/Rituximab Combo Achieves Durable, High MRD-Negative Status in CLL
December 5th 2018The combination of venetoclax and rituximab for relapsed/refractor chronic lymphoblastic leukemia produced high rates of undetectable minimal residual disease, which was associated with prolonged progression-free survival, a new analysis of a randomized trial showed.
Read More
Venetoclax With HMAs Shows Promise in AML for Patients Ineligible for High-Dose Chemo
December 3rd 2018More than 70% of older patients ineligible for intensive chemotherapy for acute myeloid leukemia had complete responses to venetoclax combined with hypomethylating agents, preliminary results from clinical trials have shown.
Read More
ACCC Relaunches Immuno-Oncology Initiative to Meet Evolving Needs of Oncology Community
November 30th 2018The Association of Community Cancer Centers announced the relaunch of the ACCC Immuno-Oncology Institute including an online resource portal for oncology professionals to find practical, proactive strategies for the effective delivery of new and emerging therapies.
Read More
Keeping Up With Hematologic Advances in Clayton
November 21st 2018We headed to Clayton, Missouri for a State of the Science Summit on Hematologic Malignancies, which focused on novel agents in chronic lymphocytic leukemia, advances in acute myeloid leukemia, progress in myeloproliferative neoplasms, and more.
Read More
Getting Educated With GI Cancer Therapies in Newport Beach
November 15th 2018We headed to Newport Beach, California, for a State of the Science Summit on Gastrointestinal Cancers, which focused on the evolving paradigms of colorectal cancer, pancreatic cancer, neuroendocrine tumors, gastric cancer, and hepatocellular carcinoma.
Read More